|
|
|
| Efficacy of bevacizumab combined with paclitaxel for treating patients with ovarian cancer and its influence on the immune function of the patients |
| 1.Funan County People's Hospital, Fuyang, Anhui Province, 236300; 2.The Second People's Hospital of Fuyang City, Fuyang, Anhui Province |
|
|
|
|
Abstract To study the efficacy of bevacizumab combined with paclitaxel for treating patients with ovarian cancer, and to analyze its influence on the immune function of the patients. Methods:84 patients with ovarian cancer who received treatment in the hospital were selected and divided into two groups (42 cases in each group) by random number table method from January 2018 to January 2023. The patients in the two groups were given carboplatin regimen, and the patients in the control group were given paclitaxel treatment and the patients in the experimental group were given bevacizumab combined with paclitaxel treatment. The clinical therapeutic effect, the immune function, the ovarian blood flow parameters, the changes of tumor markers and the occurrence of adverse reactions of the patients were compared between the two groups. Results: The total effective rate (76.2%) of the patients in the experimental group was significantly higher than that (52.4%) of the patients in the control group. The values of CD3, CD4, CD8 and NK of the patients in the two groups after treatment had increased significantly, and which (67.23±4.22%, 33.02±3.21%, 28.81±3.23% and 25.58±2.71%) of the patients in the experimental group were significantly higher than those (61.04±4.05%, 28.47±3.12%, 24.14±3.04% and 22.68±2.04%) of the patients in the control group. The levels of HE4, CA125 and CEA of the patients in the two groups after treatment had decreased significantly, and which (22.80±11.41 pmol/L, 15.91±9.41 U/ml and 2.24±0.78μg/L) of the patients in the experimental group were significantly lower than those (57.56±17.06 pmol/L, 30.84±13.24) U/ml and 4.83±1.26μg/L) of the patients in the control group (all P<0.05). The thrombocytopenia, leukopenia, liver dysfunction and gastrointestinal reactions of the patients in the two groups were their main adverse reactions, but which of the patients had no significant difference between the two groups (P＞0.05). Conclusion: Bevacizumab combined with paclitaxel has the better effect in the treatment of the patients with ovarian cancer, which may be related to the effective improvement of the immune function of the patients.
|
|
|
|
|
|
|
|
|
